EUVIMEDEUVIMED entdecken
Open Access

Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease

Yannan Huang, Laura Sompii-Montgomery, Jessica Patti, Alex Pickering, Shima Yasin, Thuy Do, Elizabeth Baker, Denny Gao iD, Rabheh Abdul-Aziz, Edward M Behrens, Scott Canna iD, Matthew Clark und 25 weitere

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Yannan Huang und 36 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Lung Diseases, Macrophage Activation Syndrome. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening disease complication. Key questions remain regarding clinical course and optimal treatment approaches. The objectives of the study were to detail management strategies after SJIA‐LD detection, characterize overall disease courses, and measure long‐term outcomes.

Methods

This was a prospective cohort study. Clinical data were abstracted from the electronic medical record, including current clinical status and changes since diagnosis. Serum biomarkers were determined and correlated with presence of LD.

Results

We enrolled 41 patients with SJIA‐LD, 85% with at least one episode of macrophage activation syndrome and 41% with adverse reactions to a biologic. Although 93% of patients were alive at last follow‐up (median 2.9 years), 37% progressed to requiring chronic oxygen or other ventilator support, and 65% of patients had abnormal overnight oximetry studies, which changed over time. Eighty‐four percent of patients carried the HLA‐DRB1*15 haplotype, significantly more than patients without LD. Patients with SJIA‐LD also showed markedly elevated serum interleukin‐18 (IL‐18), variable C‐X‐C motif chemokine ligand 9 (CXCL9), and significantly elevated matrix metalloproteinase 7. Treatment strategies showed variable use of anti–IL‐1/6 biologics and addition of other immunomodulatory treatments and lung‐directed therapies. We found a broad range of current clinical status independent of time from diagnosis or continued biologic treatment. Multidomain measures of change showed imaging features were the least likely to improve with time.

Conclusion

Patients with SJIA‐LD had highly varied courses, with lower mortality than previously reported but frequent hypoxia and requirement for respiratory support. Treatment strategies were highly varied, highlighting an urgent need for focused clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileLung DiseasesMacrophage Activation SyndromeChildHumansProspective StudiesLungDisease Progression

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Harvard Medical School, Boston, Massachusetts.
  • University of Iowa Carver College of Medicine, Iowa City.
  • University at Buffalo, Oishei Children's Hospital, Buffalo, New York.
  • The Children's Hospital of Philadelphia and Perelman School of Medicine at The University of Pennsylvania, Philadelphia.
  • Prisma Health Children's Hospital Upstate and University of South Carolina School of Medicine-Greenville, Greenville.

ORCID-Profile: Denny Gao, Scott Canna, Aimee O Hersh, Melissa L Mannion, Jessica Neely, Grant S Schulert

Förderung

  • NIAMS NIH HHS
  • NHLBI NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Huang, Y., Sompii-Montgomery, L., Patti, J., Pickering, A., Yasin, S., Do, T., Baker, E., Gao, D., Abdul-Aziz, R., Behrens, E. M., Canna, S., Clark, M., Co, D. O., Collins, K. P., Eberhard, B., Friedman, M., Graham, T. B., Hahn, T., Hersh, A. O., …, & Schulert, G. S. (2024). Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease. Arthritis Care & Research. https://doi.org/10.1002/acr.25234

Vancouver

Huang Y, Sompii-Montgomery L, Patti J, Pickering A, Yasin S, Do T, et al. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease. Arthritis Care & Research. 2024. doi:10.1002/acr.25234

BibTeX
@article{Huang2024,
  author = {Huang, Yannan and Sompii-Montgomery, Laura and Patti, Jessica and Pickering, Alex and Yasin, Shima and Do, Thuy and Baker, Elizabeth and Gao, Denny and Abdul-Aziz, Rabheh and Behrens, Edward M and Canna, Scott and Clark, Matthew and Co, Dominic O and Collins, Kathleen P and Eberhard, Barbara and Friedman, Monica and Graham, Thomas B and Hahn, Timothy and Hersh, Aimee O and Hobday, Patricia and Holland, Michael J and Huggins, Jennifer and Lu, Pai-Yue and Mannion, Melissa L and Manos, Cynthia K and Neely, Jessica and Onel, Karen and Orandi, Amir B and Ramirez, Andrea and Reinhardt, Adam and Riskalla, Mona and Santiago, Laisa and Stoll, Matthew L and Ting, Tracy and Grom, Alexei A and Towe, Christopher and Schulert, Grant S},
  title = {Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25234}
}
Kostenlos starten →